Heparin Cryoprecipitation Reduces Plasma Levels of Non-Traditional Risk Factors for Atherosclerosis in vitro

Abstract

Aims: To show that heparin cryoprecipitation (HCP), an in vitro method of plasma purification, reduces the levels of in vivo modified proteins and non-traditional risk factors from plasma of atherosclerotic hemodialysis (HD) patients. Methods: HCP was applied to plasma obtained from HD patients and controls, forming a precipitate – cryogel. Levels of fibrinogen, albumin, CRP, TNF-α, IL-6, advanced oxidation protein products, carbonylated fibrinogen and carbonylated albumin were determined in plasma before and after applying HCP and in the cryogel. Results: Treatment of HD plasma with HCP, beyond the significant reduction of the increased levels of all the above-mentioned molecules, reduced fibrinogen, TNF-α, carbonylated fibrinogen and carbonylated albumin to control levels which were simultaneously found in the cryogel. Conclusions: HCP applied to plasma enables the simultaneous precipitation of modified molecules and circulating non-traditional risk factors for atherosclerosis. This study may serve as a base for the future development of a clinical purification technique.

A Protocol for the Preparation of Cryoprecipitate and Cryodepleted Plasma

“…Cryoprecipitate prepared from CPD anticoagulated plasma has been shown to give a higher yield of Factor VIII compared to ACD anticoagulated plasma (11). The preparation of cryoprecipitate from plasma anticoagulated with noncitrate anticoagulants (e.g., heparin) may yield a different profile of precipitated proteins (12).…”

A Protocol for the Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Studies

“…The preparation of cryoprecipitate from plasma anticoagulated with non-citrate anticoagulants (e.g. heparin) may yield a different profile of precipitated proteins [12].…”